Antibody Drug Conjugates (ADCs) that are formed by monoclonal antibodies along with linkers and chemotherapy drugs are having better tumor targeting action with less toxic side effects than the traditionally developed chemotherapy drugs. ADCs combine the unique targeting nature of monoclonal antibodies with the cytotoxic drugs that are having the ability to kill the cancer cells. These will allow differentiation between healthy and diseased tissues. Advancements made to couple monoclonal antibodies with cytotoxic drugs allow better control of drug pharmacokinetics, and thus, significantly improve drug delivery to target tissue. Now, Potent novel anti-cancer drugs can be used to target cancers by minimizing the exposure of healthy tissue.
The recent approval of four ADCs (Adcetris, Kadcyla, Mylotarg and Besponsa) in the global market and presence of a strong pipeline of such drugs are highlighting the potential for new therapeutic innovations in this industry. The global antibody drug conjugates industry has been growing rapidly over the recent years as the global sales of Adcetris and Kadcyla have been showing rapid growth after their approval. Due to the targeting and improved technology, ADCs are gaining a lot of attention from both small and large pharmaceutical companies. Currently, there found more than 50 ADCs in clinical trials, and it has been predicted that three to four ADCs will be commercialized in the area of refractory hodgkin lymphoma, glioblastoma, small cell lung cancer, breast cancer, and ovarian cancer during the forecast period. FDA has granted priority review for ADC from Immunopharma (Sacituzumab Govitecan), which if approved would be first ADC based biologics for the treatment of Metastatic Triple-negative Breast Cancer. It has been witnessed that the maximum number of clinical trials are being conducted for lymphoma.
The high cost of production, regulatory challenges, and lack of experienced manufacturers are slowing down the global ADCs market growth. Linking drug compounds to a careful target selection, the controlling and knowing of ADC off-target toxicities, a better insight on ADCs mechanism of action, and also the selection of clinical settings like patient selection, dosing regimen of the molecules that are going to bring the highest clinical benefit are the challenges that are going to add to the drug therapeutic index improvement. The major drivers for the global antibody drug conjugates market include increasing incidences of cancer types, efforts regarding patent protection, advances in drug linking technologies, and increasing demand to the antibody drug conjugates.
The global ADCs market is segmented on the basis of type, product, technology, application, and end-user.
On the basis of type: Monoclonal antibodies, linker, drug/toxin, and others.
On the basis of application: Leukemia, kidney cancer, pancreas cancer, prostate cancer, ovary cancerlung cancer, glioblastoma, colon cancer, breast cancer, solid tumors, skin cancer multiple myeloma, lymphoma, and other cancers. The leukemia segment is further segmented into Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML), and Chronic Myeloid Leukemia (CML).
On the basis of product: Adcertis, Kadcyla, and others.
On the basis of technology: ImmunoGen technology, Seattle Genetics technology, Immunomedics technology, and others.
On the basis of end-user: Hospitals, specialized cancer centers, academic research institutes, biotechnology companies, biopharmaceutical companies, and others.
The global ADCs market consists of four regions, namely, America, Europe, Asia Pacific, and the Middle East and Africa. Americas are dominating the global ADCs market owing to the technological innovation, the contribution of nanotechnology for developing Antibody Drug Conjugates (ADC), advancement in manufacturing processes. The European ADCs market stood as the second largest market. The Asia Pacific is known to be the emerging market in the global ADCs market.
Some of the major players in the global ADCs market include Seattle Genetics, ImmunoGen, Inc., Roche Holding AG, Genentech, Concortis Biotherapeutics, Agensys, Inc., Antikor, Immunomedics, Pfizer Inc., Celldex Therapeutics, and others.
Report Description: The report covers in-depth analysis on Global Antibody Drug Conjugates Market. The report assesses the Antibody Drug Conjugates pipeline by stage of development (early development, pre-clinical, clinical and in approval), by application (Hodgkin lymphoma, glioblastoma, small cell lung cancer, breast cancer, and others). In addition, the report includes key insights on other development activities, including (but not limited to) – licensing (In and Out), collaborations, acquisitions, reimbursement, patent, and regulatory designations.
The report includes in-depth company profiles of key players in Global Antibody Drug Conjugates Market. The company profile includes key information on overview, financial highlights, product portfolio, business strategies, and key recent developments.
The report highlights information on emerging companies with potentially disruptive technologies and new market entrants.
Data Collation (Primary & Secondary)
In-house Estimation (Based on proprietary databases and Models)
Market-related information is assembled from both primary and secondary sources.
Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others.
Top-down and bottom-up approaches: The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained.